Bremelanotide (Vyleesi) Guide
FDA-Approved HSDD Treatment
Bremelanotide is an FDA-approved melanocortin receptor agonist for acquired generalized hypoactive sexual desire disorder in premenopausal women. It is not indicated to enhance sexual performance or to treat men.
Prescription Melanocortin Therapy
Bremelanotide (Vyleesi) is a melanocortin receptor agonist indicated for acquired generalized hypoactive sexual desire disorder in premenopausal women. The FDA label does not support use for men or for sexual performance enhancement.
Track the exact dose, timing, and any adverse effects if you are following a prescribed plan, since nausea, flushing, headache, and injection-site reactions are the most common tolerability issues.
What Is Bremelanotide (PT-141)?
Bremelanotide is a prescription medication with a specific FDA indication: acquired generalized hypoactive sexual desire disorder in premenopausal women. It is not indicated to enhance sexual performance and should not be described as a general aphrodisiac.
Because it can raise blood pressure transiently and commonly causes nausea, the label recommends careful attention to cardiovascular risk, dose timing, and tolerability.
Administration Highlights
Indicated only for premenopausal women with acquired generalized HSDD
Injected subcutaneously as needed before anticipated sexual activity
Do not use more than one dose in 24 hours
Do not use more than 8 doses per month
Common adverse effects include nausea, flushing, headache, and vomiting
Dosing Protocol
The labeled dose is 1.75 mg subcutaneously as needed at least 45 minutes before anticipated sexual activity.
Do not exceed one dose within 24 hours or eight doses in a month.
The label advises against use in men and in postmenopausal women.
Side Effects & Safety
Expected Effects
Nausea, flushing, headache, vomiting, and injection-site reactions
Skin-Related
Focal hyperpigmentation can occur and may persist in some patients
Key Questions
What is Bremelanotide used for?
It is approved for acquired generalized hypoactive sexual desire disorder in premenopausal women, not for performance enhancement.
What side effects should I watch for?
Nausea, flushing, headache, and hyperpigmentation are the main tolerability issues to monitor.
Guide FAQs
Bremelanotide is a prescription melanocortin receptor agonist approved for acquired generalized hypoactive sexual desire disorder in premenopausal women.
Yes. Shotlee supports tracking Bremelanotide doses, side effects, and health metrics. It is free to use.
References
Track Your Bremelanotide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free